JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

DexCom Inc

Open

SectorHealthcare

68.41 -0.06

Overview

Share price change

24h

Current

Min

67.88

Max

69.41

Key metrics

By Trading Economics

Income

74M

180M

Sales

121M

1.2B

P/E

Sector Avg

49.739

37.003

Profit margin

15.539

Employees

10,200

EBITDA

90M

309M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.2% upside

Dividends

By Dow Jones

Next Earnings

30 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-7.4B

28B

Previous open

68.47

Previous close

68.41

News Sentiment

By Acuity

50%

50%

154 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

DexCom Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jul 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

Peer Comparison

Price change

DexCom Inc Forecast

Price Target

By TipRanks

40.2% upside

12 Months Forecast

Average 97.06 USD  40.2%

High 106 USD

Low 85 USD

Based on 22 Wall Street analysts offering 12 month price targets forDexCom Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

19

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

71.66 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

154 / 373 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat